Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.40

-1.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (25894)	2/18/2008 12:37:10 PM
From: Biotech Jim	Read Replies (1) of 52153

There is dramatic news on the science front in terms of remyelination in CNS demyelination models. Richard Ransohoff at the Cleveland Clinic, who is a neurologist, treats patients and does basic work in experimental autoimmune encephalopathy models in rodents. There is an emerging story on the role of the chemokine receptor CXCR2 knockout in dramatic remyelination in this model of MS. Look for a soon to appear publication on this in the Journal of Experimental Medicine, with the 1st author being Segal. BTW, Dr. Ransohoff does see MS patients in his group neurology clinic practice. He does treat selected patients with Tysabri, though he has bee quite conservative on its use. He also published a note recently in NEJM that summarizes his perspective on drug use (ie Tysabri) in MS patients. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next